ascopubs.org

The effect of adjuvant carboplatin-based chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials.

A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy. Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted ...
ascopubs.org

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) This trial adds to the ...
Healio

‘Worth pursuing’: Radiotherapy with carboplatin-paclitaxel similar to cisplatin for HNSCC

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
inkl

One in Four Carboplatin Rationing Decisions at Dana-Farber Did Not Match Its Own Policy During the 2023 Shortage

A Dana-Farber review found that 26% of carboplatin rationing decisions during the 2023 shortage did not match policy. What it ...
Cancer Network

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Cisplatin/etoposide and carboplatin/etoposide achieved median OS of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer. Therapy with either cisplatin and ...